



(12) Translation of
European patent specification

(11) NO/EP 3224256 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 401/14 (2006.01) C07D 231/14 (2006.01)
A61K 31/415 (2006.01) C07D 401/06 (2006.01)
A61K 31/454 (2006.01) C07D 401/10 (2006.01)
A61K 31/4709 (2006.01) C07D 403/10 (2006.01)
A61K 31/497 (2006.01) C07D 409/14 (2006.01)
A61K 31/506 (2006.01) C07D 413/14 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.10.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.07.03
(86)	European Application Nr.	15804210.1
(86)	European Filing Date	2015.11.26
(87)	The European Application's Publication Date	2017.10.04
(30)	Priority	2014.11.27, GB, 201421083
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA MD
(73)	Proprietor	Kalvista Pharmaceuticals Limited, Porton Science Park Bybrook Road, Porton DownWiltshire SP4 0BF, Storbritannia
(72)	Inventor	DAVIE, Rebecca Louise, c/o KALVISTA PHARMACEUTICALS LIMITED, Porton Science Park Bybrook Road Porton Down, Wiltshire SP4 0BF, Storbritannia EDWARDS, Hannah Joy, c/o KALVISTA PHARMACEUTICALS LIMITED, Porton Science Park Bybrook Road Porton Down, Wiltshire SP4 0BF, Storbritannia EVANS, David Michael, c/o KALVISTA PHARMACEUTICALS LIMITED, Porton Science Park Bybrook Road Porton Down, Wiltshire SP4 0BF, Storbritannia HODGSON, Simon Teanby, Orchard House The Avenue Ampthill, Bedfordshire MK45 2NR, Storbritannia
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54)	Title	N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS,
(56)	References Cited:	WO-A1-2007/113289, WO-A1-2014/108679, WO-A1-2005/049578, WO-A1-2014/188211,

WO-A1-2013/111108, WO-A1-2012/017020

DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 December 2008 (2008-12-18), Chemical catalogue: AKos Consulting and Solutions GmbH: "2-Thiophenecarboxamide", XP055244196,

DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 January 2009 (2009-01-22), Chemical catalogue: AKos Consulting and Solutions GmbH: "2-Thiophenecarboxamide, 4-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(4-morpholinyl)", XP055244198, Database accession no. 1094996-93-6


DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2 August 2009 (2009-08-02), Chemical Catalogue: Ambinter: "1H-Pyrazole-4-carboxamide, N-[[4-(acetylamino)phenyl]methyl]-3-(4-methylphenyl)-1-[(4-methylphenyl)methyl]-", XP055244636, Database accession no. 1171693-25-6

DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 August 2012 (2012-08-03), Chemical catalogue: Ukrorgsyntez Ltd: "1H-Pyrazole-4-carboxamide, N-[[4-[(2-amino-2-oxoethyl)amino]carbonyl]phenyl]methyl]-3-(4-methylphenyl)-1-[(4-methylphenyl)methyl]-", XP055244204, Database accession no. 1386189-59-8


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav


1. Forbindelse valgt fra:




;






;



;



;



og farmasøytisk akseptable salter og solvater derav.

2. Forbindelse ifølge krav 1 valgt fra:


3. Forbindelse ifølge krav 1 valgt fra:



4. Forbindelse ifølge krav 1 valgt fra:


og farmasøytisk akseptable salter og solvater derav.

5. Forbindelse ifølge krav 1 valgt fra:




og farmasøytisk akseptable salter og solvater derav.

5 6. Forbindelse ifølge krav 1 valgt fra:




og farmasøytisk akseptable salter og solvater derav.

7. Forbindelse ifølge krav 1 valgt fra:



og farmasøytisk akseptable salter og solvater derav.

8. Forbindelse ifølge krav 1 valgt fra:



5 og farmasøytisk akseptable salter og solvater derav.

9. Farmasøytisk sammensetning omfattende en forbindelse, eller et farmasøytisk akseptabelt salt eller solvat derav, ifølge et hvilket som helst av kravene 1 til 8, og en farmasøytisk akseptabel bærer, fortynningsmiddel eller eksipiens.